before few years, the united kingdom has witnessed a revolution in health-related pounds‑decline treatments — from the introduction of semaglutide (Wegovy®) for the expanding acceptance of tirzepatide (Mounjaro®). Now, A further title is drawing notice in equally scientific and public wellbeing c